110 related articles for article (PubMed ID: 8911006)
1. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.
von Specht BU; Lücking HC; Blum B; Schmitt A; Hungerer KD; Domdey H
Vaccine; 1996 Aug; 14(12):1111-7. PubMed ID: 8911006
[TBL] [Abstract][Full Text] [Related]
2. The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man.
von Specht BU; Lücking HC; Blum B; Schmitt A; Hungerer KD; Domdey H
Behring Inst Mitt; 1997 Feb; (98):326-37. PubMed ID: 9382756
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
Mansouri E; Gabelsberger J; Knapp B; Hundt E; Lenz U; Hungerer KD; Gilleland HE; Staczek J; Domdey H; von Specht BU
Infect Immun; 1999 Mar; 67(3):1461-70. PubMed ID: 10024596
[TBL] [Abstract][Full Text] [Related]
4. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
6. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
Baumann U; Mansouri E; von Specht BU
Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
Larbig M; Mansouri E; Freihorst J; Tümmler B; Köhler G; Domdey H; Knapp B; Hungerer KD; Hundt E; Gabelsberger J; von Specht BU
Vaccine; 2001 Mar; 19(17-19):2291-7. PubMed ID: 11257350
[TBL] [Abstract][Full Text] [Related]
8. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
9. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
[TBL] [Abstract][Full Text] [Related]
10. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
[TBL] [Abstract][Full Text] [Related]
11. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
[TBL] [Abstract][Full Text] [Related]
13. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa.
Knapp B; Hundt E; Lenz U; Hungerer KD; Gabelsberger J; Domdey H; Mansouri E; Li Y; von Specht BU
Vaccine; 1999 Mar; 17(13-14):1663-6. PubMed ID: 10194820
[TBL] [Abstract][Full Text] [Related]
14. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
[TBL] [Abstract][Full Text] [Related]
15. [Study on Construction of Recombinant Bb-pGEX-
Liu X; Li WG; Luo GX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):13-17. PubMed ID: 29737082
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
[TBL] [Abstract][Full Text] [Related]
17. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
18. [Immunization with Bifidobacterium bifidum-vectored OprI vaccine of Pseudomonas aeruginosa enhances inhibitory effect on P. aeruginosa in mice].
Liu X; Li W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Aug; 33(8):1040-1044. PubMed ID: 28871943
[TBL] [Abstract][Full Text] [Related]
19. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.
Jang IJ; Kim IS; Park WJ; Yoo KS; Yim DS; Kim HK; Shin SG; Chang WH; Lee NG; Jung SB; Ahn DH; Cho YJ; Ahn BY; Lee Y; Kim YG; Nam SW; Kim HS
Vaccine; 1999 Jan; 17(2):158-68. PubMed ID: 9987150
[TBL] [Abstract][Full Text] [Related]
20. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
Gabelsberger J; Knapp B; Bauersachs S; Enz UI; von Specht BU; Domdey H
Behring Inst Mitt; 1997 Feb; (98):302-14. PubMed ID: 9382754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
